2.1. Patient Characteristics
kidney stones, kidney abnormalities
KIDNEY STONE
This RCT was approved by the Institutional Review Board of Applied Science Private University (ASU) (protocol number 2020-PHA-16) and undertaken between October 2020 and December 2020. The clinical trial was conducted following the Helsinki Declaration. Each individual who was enrolled provided informed consent for this clinical trial. With an average baseline age of 38.37 ± 9.77 years, volunteers included were Jordanian and from ASU staff and their families (ranging from 30 to 66). Eligible participants were included in the trial depending on a diagnosis of VDD confirmed by medical consultants at Ibn Al-Haytham clinical laboratories. Because prolonged VD3 administration is related to the formation of kidney stones, patients with kidney abnormalities were excluded from the study [